PTEN and neoplasm: Tumor cell lines characterized for the mutational status of KRAS, BRAF, and PTEN (Table 1 and S1) were exposed to either the MEK inhibitor Trametinib or the mTOR inhibitor Everolimus (both at concentrations ranging from 0.1 to 1000 nM) for 72 h and half maximal inhibitory concentration (IC50) were derived, based on the assessment of cell viability (Table S1).